View Older Stories View More Recent Stories

Jun 11, 2025 03:01PM Biofrontera Inc. (BFRI) Negotiating Changes to its Cooperation with Biofrontera AG
Jun 11, 2025 03:00PM BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
Jun 3, 2025 02:30PM Biofrontera Inc. (BFRI) Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
Jun 3, 2025 02:30PM Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
May 15, 2025 12:17PM Biofrontera (BFRI) Announces New Patent Protection on Ameluz until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz
May 15, 2025 12:17PM Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatm
Jan 8, 2025 09:51AM Biofrontera (BFRI) Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz-Photodynamic Therapy In The Treatment Of Superficial Basal Cell Carcinoma
Jan 8, 2025 09:50AM Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
Dec 23, 2024 09:31AM Biofrontera Inc. (BFRI) Announces 100 RhodoLED XL Machines Now Placed in US Market
Dec 23, 2024 09:30AM Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
Nov 13, 2024 05:15PM Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
Oct 14, 2024 10:30AM Biofrontera (BFRI) Announces Database Lock Of Phase 3 Study Of Ameluz-Photodynamic Therapy In The Treatment Of sBCC
Oct 14, 2024 10:30AM Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
Oct 7, 2024 08:45AM Biofrontera (BFRI): FDA Approves Use of Up To Three Tubes of Ameluz Topical Gel, 10% In One Treatment
Oct 7, 2024 08:45AM FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
Sep 25, 2024 10:45AM Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
Aug 14, 2024 04:30PM Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
Jun 24, 2024 08:30AM Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
May 15, 2024 04:45PM Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
Mar 26, 2024 04:30PM Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
Mar 15, 2024 08:12PM CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Mar 15, 2024 04:56PM Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Feb 23, 2024 08:40AM Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
Feb 20, 2024 08:13AM Biofrontera Inc. (BFRI) Restructures Supply Agreement with Biofrontera AG
Feb 20, 2024 08:10AM Biofrontera Inc. (BFRI) Announces $16M Private Placement
Feb 20, 2024 08:10AM Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
Feb 20, 2024 08:05AM Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules
Feb 5, 2024 05:18PM Biofrontera Inc. (BFRI) Announces FDA Filing of Supplemental New Drug Application for Ameluz
Feb 5, 2024 05:15PM Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use
Nov 9, 2023 05:10PM Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
Oct 10, 2023 09:06AM Biofrontera Inc. (BFRI) Receives FDA Approval for New Formulation of Ameluz
Oct 10, 2023 09:00AM Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)
Oct 5, 2023 09:00AM Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
Oct 4, 2023 08:34AM Biofrontera (BFRI) Reports Prelim Q3 Revenue of $8.7-$9M
Oct 4, 2023 08:30AM Biofrontera Inc. Announces Preliminary Third Quarter Revenues
Aug 29, 2023 08:03AM Biofrontera Inc. (BFRI) Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
Aug 29, 2023 08:00AM Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
Aug 28, 2023 08:02AM Biofrontera Inc. (BFRI) Announces Positive Results from Phase 1 Safety Study of Photodynamic Therapy with Three Tubes of Ameluz
Aug 28, 2023 08:00AM Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)
Aug 11, 2023 07:00AM Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
Aug 10, 2023 08:30AM Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
Aug 4, 2023 08:30AM Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023
Jul 13, 2023 09:02AM Biofrontera (BFRI) Reports Prelim Q2 Revenue of $5.7M-$5.9M
Jul 13, 2023 09:00AM Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%
Jul 12, 2023 08:04AM Biofrontera Inc. (BFRI) Appoints Dr. Heikki Lanckriet to its Board
Jul 12, 2023 08:00AM Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors
Jul 3, 2023 09:17AM Biofrontera Inc. (BFRI) Announces 1-for-20 Reverse Stock Split
Jul 3, 2023 09:15AM Biofrontera Inc. Announces 1-for-20 Reverse Stock Split
Jun 12, 2023 09:00AM Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.
Jun 1, 2023 09:15AM Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT
View More Recent Stories View Older Stories